Genomic questions
Coauthored research examines gene-expression and sequencing classifiers in thyroid and pulmonary diagnostic settings.
Trace the researchMolecular biologist · Diagnostics innovator
Giulia
Kennedy, PhD
Co-founder and Chief Scientific Officer, PinkDx
A biochemistry foundation. A career in molecular diagnostics. A continuing interest in how research can inform clinical decisions.
A career read as a genome.
A living genome
A career, read
as connections.
Organisations on one strand. Research and contribution on the other. Follow four documented chapters, or choose Reading view for the complete, motion-free narrative.
Strand A · Organisations & rolesStrand B · Research & contribution
- Education & trainingInstitution
Chapter 01 / 04
A scientific foundation
Early career · dates not established
Biochemistry and postdoctoral training
A foundation in biochemistry and research training preceded her work in molecular diagnostics.
Explore this chapter - AffymetrixCompany
Chapter 02 / 04
Affymetrix
2000–2008
Senior Director
An eight-year Senior Director tenure at Affymetrix followed earlier scientific roles at Chiron and Millennium Pharmaceuticals.
Explore this chapter - VeracyteCompany
Chapter 03 / 04
Veracyte
2008–2022
Chief Scientific Officer · Chief Medical Officer
Scientific and medical leadership connected genomic classifiers to questions in thyroid and pulmonary diagnostics.
3 research areas · 6 selected papers · 1 documented milestone
Explore this chapter - PinkDxFounder
Chapter 04 / 04
PinkDx
Documented from 2024
Co-founder and Chief Scientific Officer
At PinkDx, Kennedy leads scientific strategy and translational research focused on gynecologic cancer.
2 research areas · 1 selected papers · 2 documented milestones
Explore this chapter
Helix placement follows chapter sequence, not a numerical date scale. Dated roles and uncertain periods are identified in each chapter.
Research, in relation
Questions connect.
From thyroid and pulmonary diagnostics to exploratory gynecologic-cancer research, these areas are linked by source-identified papers—not by imagined connections.
Explore the researchRead the connections
Thyroid diagnostics
Molecular classification of thyroid nodules and expressed genomic signals.
Career context: Veracyte
1 selected paper · first recordPulmonary risk & interstitial disease
Genomic classifiers studied in usual interstitial pneumonia and lung-cancer risk assessment.
Career context: Veracyte
4 selected papers · first recordTranscriptomics & classification
RNA-sequencing and machine-learning methods used to investigate diagnostic questions.
Career context: VeracytePinkDx
2 selected papers · first recordEndometrial cancer research
Exploratory evidence for molecular signals in vaginal swabs; clinical validation remains necessary.
Career context: PinkDx
1 selected paper · first record
Evidence, not superlatives
What the work
points toward.
Translation
Issuer filings document scientific and medical leadership at Veracyte across 2008–2022; they do not quantify a personal patient outcome.
See the chapterA new sample
A 2026 PinkDx coauthored paper reported endometrial-cancer molecular signals in vaginal swabs. Its exploratory subset is not clinical validation.
Read the caveatIn her words · PinkDx, 2026
“Our focus is not just discovery, but translation — designing molecular diagnostics that can move into real-world clinical decision-making. That's the lens through which this work was conceived.”
— Giulia Kennedy, in a PinkDx announcement about exploratory endometrial-cancer research
Selected coauthored research
Published work.
2026
Whole-transcriptome sequencing and machine learning detect molecular signatures of endometrial cancer in non-invasive vaginal swabs
Context: Preliminary subset analysis; not evidence of a clinically validated screening or diagnostic test.
2022
2010
Documented relationships
A documented network
A line here means a recorded role, training or publication affiliation. It does not infer a permanent team or employment from coauthorship.
- Co-founderGiulia C. KennedyPinkDx
Co-founder and Chief Scientific Officer · Documented at public launch 2024-04-25; exact start date unknown
View record - Co-founderBonnie AndersonPinkDx
Co-founder, Chair and CEO
View record - Co-founderTim McMeekanPinkDx
Co-founder, CFO and CBO at launch
View record - Affiliation on cited publicationJason D. WrightColumbia University Irving Medical Center
2026 paper coauthor affiliation
View record - Affiliation on cited publicationPedro T. RamirezHouston Methodist Hospital
2026 paper coauthor affiliation
View record - Affiliation on cited publicationAndrea MarianiMayo Clinic
2026 paper coauthor affiliation
View record
Evidence can make room for possibility
From signal
to bloom.
At PinkDx, the current research question concerns whether a less invasive sample can yield meaningful molecular insight. The 2026 publication is exploratory; broader validation is the next question.
Explore the PinkDx chapter ↗